Last reviewed · How we verify
Acetazolamide Levamisole
This combination drug pairs acetazolamide (a carbonic anhydrase inhibitor) with levamisole (an immunomodulator) to reduce intraocular pressure while enhancing immune function.
Acetazolamide combined with Levamisole is under investigation for the treatment of hepatocellular carcinoma (HCC). A Phase 3 clinical trial is ongoing with 50 participants, aiming to evaluate its efficacy and safety.
At a glance
| Generic name | Acetazolamide Levamisole |
|---|---|
| Sponsor | The First Affiliated Hospital of Zhengzhou University |
| Drug class | Carbonic anhydrase inhibitor + immunomodulator combination |
| Target | Carbonic anhydrase II (acetazolamide component); levamisole target unclear in this context |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Glaucoma |
| Phase | Phase 3 |
Mechanism of action
Acetazolamide inhibits carbonic anhydrase in the ciliary body, decreasing aqueous humor production and lowering intraocular pressure. Levamisole acts as an immunostimulant, enhancing T-cell function and potentially providing adjunctive therapeutic benefit. The combination targets both the mechanical and immunological aspects of glaucoma or related ocular conditions.
Approved indications
- Glaucoma or elevated intraocular pressure (investigational combination approach)
Common side effects
- Paresthesia
- Metabolic acidosis
- Hypokalemia
- Agranulocytosis (levamisole-related)